The FDA's recent announcement regarding Eli Lilly's drugs being removed from the shortage list has led to a significant drop in Hims & Hers Health's stock price. Analyst opinions indicate that this shift could hinder the commercial viability of similar compounded products, as it effectively allows Eli Lilly to meet market demands.
Hims & Hers asserts that the FDA's declaration does not impact its business model. A spokesperson mentions that their compounded injectable, which is based on semaglutide, is not directly affected because it does not imitate the now-available tirzepatide products.
Collection
[
|
...
]